Adverse Reaction Signaling and Disproportionality Analysis: An Update

Drug Information Journal

Volumn 46, Issue 6, 2012, Pages 708-714

  Faich, Gerald ^a   Morris, Jonathan ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

AERS; data mining; disproportionality; pharmacovigilance; signal detection

Indexed keywords

ALGORITHM; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CHI SQUARE DISTRIBUTION; DATA ANALYSIS; DATA BASE; DATA MINING; DRUG SURVEILLANCE PROGRAM; EPIDEMIOLOGY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HUMAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SIGNAL DETECTION; WORLD HEALTH ORGANIZATION;

EID: 84873876862     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/0092861512453041     Document Type: Article

References (35)

1. World Health Organization. Glossary of terms used in pharmacovigilance. http://who-umc.org/Graphics/24729.pdf. Published March 2011. Accessed June 18, 2012.
2. Meyboom RH,Egberts AC,Edwards IR,Hekster YA,de Koning FH,Gribnau FW.Principles of signal detection in pharmacovigilance.Drug Saf. 1997;16:355-365.
3. Hauben M,Aronson J.Defining signal and its subtypes.Drug Saf. 2009;32 (2): 99-110.
4. US FDA. Guidance for industry regarding good pharmacovigilence practices and pharmacoepidemiological assessment. http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126834.pdf. Published March 2005. Accessed June 18, 2012.
5. Management of Safety Information from Clinical Trials: Report of CIOMS Working Group VI. Geneva, Switzerland: World Health Organization; 2005:.
6. Practical Aspects of Signal Detection in Pharmacovigilance: Report of CIOMS Working Group VIII. Geneva, Switzerland: World Health Organization; 2010:.
7. Finney DJ.Systematic signaling of adverse reactions to drugs.Methods Inf Med. 1974;13 (1): 1-10.
8. Amery WK.Assessment of signals generated from spontaneously generated adverse events.Pharmacoepidemiol Drug Saf. 1999;8:301-304.
9. Jones JPharmacoepidemiology. 4th ed. Chichester, UK: John Wiley & Sons; 2005:391-400.Strom BL, ed. Chichester, UK: John Wiley & Sons; 2005:391-400.
10. Faich G,Clark JPharmaceutical Risk Management: Practical Application. Fetterman JEPines WLSlatko GH, ed. Washington, DC: Food and Drug Law Institute; 2008:.
11. Gogolak V.The effect of backgrounds in safety analysis: the impact of comparison cases on what you see.Pharmacoepidemiol Drug Saf. 2003;12:249-252.
12. Bate A,Evans SJW.Quantitative signal detection using spontaneous ADR reporting.Pharmacoepidemiol Drug Saf. 2009;18 (6): 427-436.
13. DuMouchel W,Pregibon D.Proceedings of the Seventh ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. New York, NY: ACM; 2001:67-76.
14. Szarfman A,Tonning JM,Doraiswamy PM.Pharmacovigilance in the 21st century: new systematic tools for an old problem.Pharmacotherapy. 2004;24 (9): 1099-1104.
15. Almenoff JS,Pattishall EN,Gibbs TG, et al.Novel statistical tools for monitoring the safety of marketed drugs.Clin Pharmacol Ther. 2007;82 (2): 157-166.
16. Bate A,Lindquist M,Edwards IR, et al.A Bayesian neural network method for adverse drug reaction signal generation.Eur J Clin Pharmacol. 1998;54:315-321.
17. Stephenson WP,Hauben M.Data mining for signals in spontaneous reporting databases: proceed with caution.Pharmacoepidemiol Drug Saf. 2007;16 (4): 359-365.
18. Hochberg AM,Reisinger SJ,Pearson RK, et al.Using data mining to predict safety actions from FDA adverse event reporting system data.Drug Information Journal. 2007;41 (5): 633-642.
19. Hauben M,Madigan D,Hochberg AM, et al.Data mining in pharmacovigilance: computational cost as a neglected performance parameter.International Journal of Pharmaceutical Medicine. 2007;21:319-323.
20. Hochberg AM,Hauben M,Pearson RK, et al.An evaluation of three signal-detection algorithms using a highly inclusive reference event database.Drug Saf. 2009;32 (6): 509-525.
21. European Medicines Agency. 2010 Pharmacovigilance Legislation. http://www.ema.europa.eu/ema/index.jsp?url=pages/regulation/general/general_content_000492.jsp&mid=WC0b01ac058033e8ad. Accessed April 20, 2012.
22. Alvarez-Requejo A,Carvajal A,Begaud B, et al.Under-reporting of adverse drug effects.Eur J Clin Pharmacol. 1998;54:483-488.
23. Evans SJ.Pharmacovigilance: a science or fielding emergencies?.Stat Med. 2000;19:3199-3209.
24. Evans SJW,Waller PC,Davis S.Use of proportional reporting ratios.Pharmacoepidemiol Drug Saf. 2001;10:483-486.
25. Evans SJW,Waller P,Davis S.Proportional reporting ratios: the uses of epidemiological methods for signal generation [abstract].Pharmacoepidemiol Drug Saf. 1998;7:S102.
26. Colman Szarfman A,Wyeth J, et al.An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system.Pharmacoepidemiol Drug Saf. 2008;17 (11): 1068-1076.
27. Sachs RM,Bortnichak EA.An evaluation of spontaneous adverse drug reaction monitoring systems.Am J Med. 1986;81 (suppl 5b): 49-55.
28. Fletcher AP.Spontaneous adverse drug reaction reporting vs event monitoring: a comparison.J R Soc Med. 1991;84:341-344.
29. Leiper JM,Lawson DH.Why do doctors not report adverse drug reactions?.Neth J Med. 1985;28:546-550.
30. Hauben M,Hochberg AM.Exenatide and pancreatitis: the importance of reporting negative findings in data mining.Pharmaceutical Medicine. 2008;22 (4): 215-219.
31. USFDA. AERS domestic and foreign reports by year. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070441.htm. Updated July 5, 2011. Accessed June 18, 2012.
32. Weber JCP.Advances in Inflammation Research. Weissmann GSamuelsson BPaoletti R, ed. New York: Raven Press; 1984:1-7.
33. Mockenhaupt MDrug Hypersensitivity. Pichler WJ, ed. Basel, Switzerland: Karger; 2007:18-31.
34. Strom BL,Melmon KL,Miettinen OS.Post marketing studies of drug efficacy.Arch Intern Med. 1985;145:1791.
35. US FDA. Reports received and reports entered into AERS by year (as of December 31, 2010). http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070434.htm.